Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Drug record: Amiloride
Multiple sclerosis: Does aggressive MS warrant aggressive treatment?
Is it time for a new global classification of multiple sclerosis?
The effect of an AFO-shaped elastic band on drop-foot gait in patients with central neurological lesions.
Phase 2 results of the RADIANCE trial: a randomized, double-blind, placebo-controlled trial of oral RPC1063 in relapsing multiple sclerosis
Individual variation of human sphingosine 1-phosphate receptor 1 coding sequence leads to heterogeneity in receptor function and drug interactions.
Diosgenin promotes oligodendrocyte progenitor cell differentiation through estrogen receptor-mediated ERK1/2 activation to accelerate remyelination.
Rectus abdominis muscle endometriotic mass in a woman affected by multiple sclerosis.
Quantitative MRI and Cerebrospinal Fluid Inflammatory Mediators in Brazilian Patients with Relapsing-Remitting Multiple Sclerosis before and after Treatment with Immunomodulators: A Longitudinal Study.
Biochemical Markers of Autoimmune Diseases of the Nervous System.
The role of growth factors as a therapeutic approach to demyelinating disease.
Naltrexone
Ximino
Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation.
Iron and Non-Iron-Related Characteristics of Multiple Sclerosis and Neuromyelitis Optica Lesions at 7T MRI.
Epidural blood patch in a patient with multiple sclerosis: is it safe?
A biopsychosocial model of resilience for multiple sclerosis.
Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment.
[Immunodepressive therapy in neurology].
[Sacral neuromodulation as second-line treatment strategy for lower urinary tract symptoms of various aetiologies: experience of a german high-volume clinic].
Novartis gains FDA approval for Gilenya(TM), a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
Two discreet subsets of CD8 T cells modulate PLP(91-110) induced experimental autoimmune encephalomyelitis in HLA-DR3 transgenic mice.
Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic Nerve
Prospective Examination of Anxiety and Depression Before and During Confirmed and Pseudoexacerbations in Patients With Multiple Sclerosis.
A gender-related action of IFNbeta-therapy was found in multiple sclerosis.
Pages
« first
‹ previous
…
168
169
170
171
172
173
174
175
176
…
next ›
last »